Abstract 6057: The IKZF1 N159Y partial tandem duplication mutant drives chromatin remodeling, B-cell developmental defects and leukemia initiation

Abstract IKZF1 N159Y, present as a partial tandem duplication (hereafter N159Y), defines a distinct subtype of B-cell precursor acute lymphoblastic leukemia (B-ALL). The mechanistic basis of leukemogenesis of this mutation, in contrast to diverse IKZF1 alterations present across the spectrum of B-ALL, is unknown. Here we elucidate mechanisms of N159Y. We generated cell lines with heterozygous or hemizygous N159Y expression. Motif enrichment, luciferase assays, and AlphaFold3 modeling were used to evaluate altered DNA interactions. Inducible knock-in mouse models and in vitro colony-forming assays assessed developmental and self-renewal phenotypes. Cell fitness and cytotoxicity assays assessed epigenetic dependency. N159Y leukemia cells displayed a characteristic gene expression signature with activation of non-B lineage pathways and repression of B-cell identity genes. N159Y bound both canonical IKZF1 motifs and neomorphic bHLH motifs. Downregulated genes were associated with super-enhancer-linked B-cell developmental regulators. ChromHMM revealed gain of active and poised enhancers driven by N159Y. In IKZF1-null NALM6 cells, N159Y bound more sites than WT. In 293T cells, N159Y repressed the ETS motif-containing MCL1 promoter. N159Y leukemia cells showed dependency on EP300 and CREBBP, and sensitivity to A-485, JQ1, and vorinostat. In mouse models, N159Y caused a marked reduction of mature B cells with expansion of aberrant B-cell precursors, and was associated with leukemia development, while also conferring abnormal self-renewal capacity in vitro. We show that N159Y is a chromatin-remodeling transcription factor mutant with neomorphic chromatin-binding. It disrupts B cell development and induces B-ALL. Citation Format: Ruth W. Wang'ondu, Devanand Bondage, Qiong Zhang, Yiming Wu, Baranda Hansen, Chun Shik Park, Prady Baviskar, Emily Backhaus-Wagner, Ilaria Iacobucci, Surbhi Sona, Huiyun Wu, Qingsong Gao, Wojciech Rosikiewicz, Beisi Xu, Hongjian Jin, Ti-Cheng Chang, Stanley Pounds, Laura Janke, Trevor Cunningham, Kristine R. Crews, Jun J. Yang, Shondra Pruett-Miller, Charles G. Mullighan. The IKZF1 N159Y partial tandem duplication mutant drives chromatin remodeling, B-cell developmental defects and leukemia initiation [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 6057.

Authors

Institutions

Publication Details

Journal
Cancer Research
Published
2026-04-03
DOI
https://doi.org/10.1158/1538-7445.am2026-6057
Primary Topic
Acute Lymphoblastic Leukemia research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Abstract 6057: The IKZF1 N159Y partial tandem duplication mutant drives chromatin remodeling, B-cell developmental defects and leukemia initiation

Prady Baviskar, Trevor Cunningham, Ti-Cheng Chang, Qingsong Gao et al.
Cancer Research
Acute Lymphoblastic Leukemia research
article

Abstract 6057: The IKZF1 N159Y partial tandem duplication mutant drives chromatin remodeling, B-cell developmental defects and leukemia initiation

Prady Baviskar, Trevor Cunningham, Ti-Cheng Chang, Qingsong Gao, Chun Shik Park, Devanand Bondage, Stanley Pounds, Surbhi Sona, Laura J. Janke, Kristine R. Crews, Wojciech Rosikiewicz, Huiyun Wu, Beisi Xu, Hongjian E. Jin, Yiming Wu, Jun J. Yang, Charles G. Mullighan, Baranda Hansen, Ilaria Iacobucci, Emily Backhaus-Wagner, Qiong Zhang, Shondra Pruett-Miller, Ruth W. Wang'ondu
article en

Abstract

Abstract IKZF1 N159Y, present as a partial tandem duplication (hereafter N159Y), defines a distinct subtype of B-cell precursor acute lymphoblastic leukemia (B-ALL). The mechanistic basis of leukemogenesis of this mutation, in contrast to diverse IKZF1 alterations present across the spectrum of B-ALL, is unknown. Here we elucidate mechanisms of N159Y. We generated cell lines with heterozygous or hemizygous N159Y expression. Motif enrichment, luciferase assays, and AlphaFold3 modeling were used to evaluate altered DNA interactions. Inducible knock-in mouse models and in vitro colony-forming assays assessed developmental and self-renewal phenotypes. Cell fitness and cytotoxicity assays assessed epigenetic dependency. N159Y leukemia cells displayed a characteristic gene expression signature with activation of non-B lineage pathways and repression of B-cell identity genes. N159Y bound both canonical IKZF1 motifs and neomorphic bHLH motifs. Downregulated genes were associated with super-enhancer-linked B-cell developmental regulators. ChromHMM revealed gain of active and poised enhancers driven by N159Y. In IKZF1-null NALM6 cells, N159Y bound more sites than WT. In 293T cells, N159Y repressed the ETS motif-containing MCL1 promoter. N159Y leukemia cells showed dependency on EP300 and CREBBP, and sensitivity to A-485, JQ1, and vorinostat. In mouse models, N159Y caused a marked reduction of mature B cells with expansion of aberrant B-cell precursors, and was associated with leukemia development, while also conferring abnormal self-renewal capacity in vitro. We show that N159Y is a chromatin-remodeling transcription factor mutant with neomorphic chromatin-binding. It disrupts B cell development and induces B-ALL. Citation Format: Ruth W. Wang'ondu, Devanand Bondage, Qiong Zhang, Yiming Wu, Baranda Hansen, Chun Shik Park, Prady Baviskar, Emily Backhaus-Wagner, Ilaria Iacobucci, Surbhi Sona, Huiyun Wu, Qingsong Gao, Wojciech Rosikiewicz, Beisi Xu, Hongjian Jin, Ti-Cheng Chang, Stanley Pounds, Laura Janke, Trevor Cunningham, Kristine R. Crews, Jun J. Yang, Shondra Pruett-Miller, Charles G. Mullighan. The IKZF1 N159Y partial tandem duplication mutant drives chromatin remodeling, B-cell developmental defects and leukemia initiation [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 6057.

Cancer ResearchVol. 86(7_Supplement)
St. Jude Children's Research Hospital (US)
Openalex Percentile: Top 24%
Acute Lymphoblastic Leukemia research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.